Personalized Medicine

feiyuebio Agnes

Feiyuebio 202204 Research Experimental operation
Feiyue group has been working in the field of medical devices for more than 20 years, with rich experience in medical device research and development, production and sales. We have our own research and sales team with special tech support of professors from affiliated universities as technical consultants.
Researcher: Mr Zeng

202204 Research Experimental operation

Aging (Aging-US)

Dr. Brian Chen, adjunct faculty at the Herbert Wertheim School of Public Health and Human Longevity Science at UC San Diego and the Chief Science Officer of FOXO Technologies, describes his experience publishing numerous papers with Aging (Aging-US).

Aging (Aging-US) papers co-authored by Dr. Chen:

Predicting physiological aging rates from a range of quantitative traits using machine learning: https://doi.org/10.18632/aging.203660

An epigenetic biomarker of aging for lifespan and healthspan: https://doi.org/10.18632/aging.101414

Leukocyte telomere length, T cell composition and DNA methylation age: https://doi.org/10.18632/aging.101293

Epigenetic clock analysis of diet, exercise, education, and lifestyle factors: https://doi.org/10.18632/aging.101168

DNA methylation-based measures of biological age: meta-analysis predicting time to death: https://doi.org/10.18632/aging.101020

Contact information - Brian Chen - bchen@foxotechnologies.com

Keywords - aging, aging clock, mortality, machine learning, epigenetic clock, DNA methylation, biomarker, healthspan, diet, lifestyle, lifespan, epigenetics, all-cause mortality

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ or connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Author Testimonial: Dr. Brian Chen - FOXO Technologies

Aging (Aging-US) published this trending editorial in Volume 14, Issue 5, entitled, “Sex matters in Alzheimer’s disease?” by researchers Sheeja Navakkode, Toh Hean Ch’ng, and Sreedharan Sajikumar from the Department of Physiology, National University of Singapore.

DOI - https://doi.org/10.18632/aging.203950 (PDF Download)

Full text - https://www.aging-us.com/article/203950

Corresponding author - Sreedharan Sajikumar - phssks@nus.edu.sg

Keywords - Alzheimer's disease, LTP, behavioural tagging, sexual dimorphism, transcriptome profiling

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at http://www.Aging-US.com​​ and connect with us:

SoundCloud - https://soundcloud.com/Aging-Us
Facebook - https://www.facebook.com/AgingUS/
Twitter - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/agingus​
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/

Aging-US is published by Impact Journals, LLC: http://www.ImpactJournals.com​​

Media Contact
18009220957
MEDIA@IMPACTJOURNALS.COM

Trending With Impact: Alzheimer’s Disease Differs Between Men and Women

Oncotarget

Oncotarget published this trending editorial in Volume 12, Issue 6, entitled, "Innovating and expanding weight loss strategies for breast cancer survivors" by researchers Dr. Jennifer Y. Sheng and Dr. Vered Stearns from The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

DOI - https://doi.org/10.18632/oncotarget.27898 (PDF Download)

Full text - https://www.oncotarget.com/article/27898/

Correspondence to - Jennifer Y. Sheng - jsheng7@jhmi.edu

Author interview - https://www.youtube.com/watch?v=8owrnhxzq7A

Author testimonial - https://www.youtube.com/watch?v=Cb8GR__ILMo

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27898

Press release - https://www.oncotarget.com/news/pr/innovating-expanding-weight-loss-strategies-for-breast-cancer-survivors/

Keywords -  breast cancer, obesity, lifestyle interventions

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Paper Spotlight: Breast Cancer Survivors and Weight Loss

Teach Me in 10

For this week's episode of Teach Me in 10, we're joined by Dr.  Leonardo Ferreira, assistant professor of microbiology and immunology at the Medical University of South Carolina and the Hollings Cancer Center.  Type 1 diabetes (T1D) is the most common form of diabetes in infants and adolescents. It occurs when the immune system targets the patient’s own insulin-producing pancreatic islet cells for destruction. Right now, the only cure for T1D is a pancreas or pancreatic islet transplant. Yet, this procedure requires life-long immunosuppression to prevent immune rejection and autoimmunity. What if we could instead re-educate the patient’s immune system to accept pancreatic islets? That's the current focus of Ferreira's research, in which he is exploring the use of regulatory T cells as living drugs to treat T1D. This approach is unique in that it focuses on the root cause of the disease, immune attack of pancreatic islets, by genetically engineering human regulatory T cells to induce tolerance to pancreatic islets. He believes this line of work will help realize the promise of immune therapy for T1D, and explains how in less than 10 minutes.

Engineering Regulatory T Cells As Living Drugs With Dr. Leonardo Ferreira

Dr. Derrick Haslem and Dr. Lincoln Nadauld from the Precision Genomics Program, Intermountain Healthcare, Saint George, UT, discuss a research paper they co-authored that was published by Oncotarget as the cover of Volume 9, Issue 15, entitled, “Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.”

DOI - https://doi.org/10.18632/oncotarget.24384

Correspondence to - Lincoln D. Nadauld - lincoln.nadauld@imail.org

Abstract
The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic cancer who received all of their care within a single institution, we evaluated the overall survival and healthcare costs for each patient. We analyzed the outcomes of 22 patients who received genomic testing and targeted therapy (precision oncology) between July 1, 2013 and January 31, 2015, and compared to 22 historically controlled patients (control) who received standard chemotherapy (N = 17) or best supportive care (N = 5). The median overall survival was 51.7 weeks for the targeted treatment group and 25.8 weeks for the control group (P = 0.008) when matching on age, gender, histological diagnosis and previous treatment lines. Average costs over the entire period were $2,720 per week for the targeted treatment group and $3,453 per week for the control group, (P = 0.036). A separate analysis of 1,814 patients with late-stage cancer diagnoses found that those who received a targeted cancer treatment (N = 93) had 6.9% lower costs in the last 3 months of life compared with those who did not. These findings suggest that precision oncology may improve overall survival for refractory cancer patients while lowering average per-week healthcare costs, resource utilization and end-of-life costs.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.24384

Press release - https://www.oncotarget.com/news/pr/precision-oncology-in-advanced-cancer-patients-improves-overall-survival-with-lower-weekly-healthcare-costs/

Keywords - precision medicine, oncology, outcomes, costs, overall survival

About Oncotarget

Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC:  https://www.ImpactJournals.com

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Author Insight: Precision Oncology Improves Patient Survival and Financial Burdens

For this Teach Me in 10 episode, we are joined by [url][link]https://www.wrh.ox.ac.uk/team/mara-artibani[/link][name]Dr. Mara Artibani[/name][/url], senior postdoc at the Ahmed Laboratory, Weatherall Institute of Molecular Medicine at the University of Oxford. In just 10 minutes, Dr. Artibani provides you with everything you need to know about ovarian cancer, what it is and how science can work to beat it.

Ovarian Cancer With Dr. Mara Artibani

The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al.

- OncoDNA treatment recommendation followed in 60% of cases
- 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA
- 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival less than 12 months, compared to a typical average of no more than six months
Gosselies, Belgium - April 17, 2018: OncoDNA ("OncoDNA or "the Company"), the healthcare technology company that collates and translates complex cancer biomarker data to make precision medicine a reality, is pleased to announce the publication of a study in the journal Oncotarget evaluating the utility of OncoDNA's comprehensive biomarker analysis and interpretation services in clinical settings.

The study, published online today and titled "The clinical impact of using complex molecular profiling strategies in routine oncology practice", found that combining advanced, comprehensive testing of cancer biomarkers with OncoDNA's proprietary cancer treatment knowledge database can enable oncologists to make better treatment decisions for their patients. This is because OncoDNA's testing combines immunohistochemistry, next generation sequencing (NGS), and other tests including inherited heart condition testing, DNA methylation, and microsatellite instability (MSI) testing, rather than the industry standard of NGS testing alone.

The study analysed samples from 1,057 late-stage and advanced grade cancer patients from over 30 different countries on four continents between January 2015 and January 2016 for whom at least one standard of care treatment had already failed. Samples were analysed either by the sequencing of a solid biopsy only - with either a hotspot panel or comprehensive panel including more than 400 genes - or the study of biomarkers determined by immunohistochemistry and other biomolecular tests, or a combination of both. In order to assess the utility of tumour profiling in clinical practice, the study also analysed the therapeutic decisions made by oncologists after receiving OncoDNA's tumour analysis and treatment recommendation.

Overall, OncoDNA's treatment recommendation was followed in 60.4% of cases and in 99% of the cases that did not follow the recommendation the cited reason was drug unavailability or cost, not clinical consideration. The vast majority of treatment decisions (93.4%) were made based on OncoDNA's combination of tests rather than NGS alone. This is a substantial increase on NGS testing alone, which will typically yield a treatment recommendation in only 30% of cases. For the cases in which OncoDNA's treatment recommendation was followed, 27% of patients had an overall survival of less than 12 months, a significant improvement for late-stage patients, who normally have a life expectancy of no more than six months.

Jean-Pol Detiffe, Chief Executive Officer of OncoDNA, said: "This dataset demonstrates the utility and power of OncoDNA's proprietary, living database and our holistic approach to genomic and molecular profiling. For oncologists, the study suggests our testing and analysis products could represent the best way to make informed therapeutic decisions in clinical practice. Not only were OncoDNA's recommendations followed in the majority of cases, but the study also suggests that our comprehensive testing and analyses could represent the best approach for obtaining useful molecular insight, while reducing physicians' exposure to irrelevant aberrations. As we continue to expand our business through Europe and beyond, these results will help raise awareness of the benefits of our product offering among oncologists and further the healthcare industry's ability to prescribe precision medicine."

Full text - https://www.oncotarget.com/article/24757/text/

Contact

OncoDNA+32 (0) 71 18 35 00

Jean-Pol Detiffe, CEO 
Jean-Francois Laes, CSO

Consilium Strategic Communications+44 (0)20 3709 5700

Amber Fennell, Sukaina Virji, Nicholas Brown, Hendrik Thys oncodna@consilium-comms.com

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Author Insight: Unique Biomarker Analysis & Interpretation Platform in Clinical Decision-making

Sekisui XenoTech

Presenter: Dr. Brian Harvey, Emeritus Professor of Molecular Medicine at the Royal College of Surgeons in Ireland

Key concepts discussed in this webinar will include:
 - Background to the clinical use of dexamethasone in treating severe COVID-19
 - Novel molecular targets of dexamethasone in treating pulmonary edema in COVID-19
 - Molecular mechanisms of inhibitory effects of dexamethasone on ion channels
 - Gender disparity in inflammatory lung disease: COVID-19, Asthma and Cystic Fibrosis
 - Molecular mechanisms of sexual dimorphism in COVID-19 and CF
 - Sex hormone-related targets in COVID-19 and CF

Abstract:
In this webinar we will discuss novel molecular targets of the steroid dexamethasone and the steroid hormone estrogen in airway disease with a focus on Covid-19, asthma and cystic fibrosis.

Dexamethasone is a synthetic steroid commonly used in the treatment of inflammatory airway disease which has found a repurposed use in the clinical management of severe COVID-19 lung disease with great success in reducing mortality. The few clinical studies ascribe the therapeutic effects of dexamethasone to its anti-inflammatory actions, however, this does not explain the steroid action on reducing pulmonary edema per se and other targets may be involved. We have recently shown effects of dexamethasone to reduce secretion across human airway cell lines by inhibiting ion channels and these novel effects of the steroid will be discussed in detail.

A gender disparity has been observed since the first reports of COVID-19 appeared with more men than women suffering severe COVID19 disease and dying from it. The molecular mechanisms for this sexual dimorphism are still unknown although the evidence points to differences in estrogen hormone levels and estrogen receptor expression and their regulation of ACE2 receptor biology, after taking into account patients age and underlying comorbidities. We know that a ‘gender gap’ also exists in other lung diseases such as asthma and cystic fibrosis. Asthma has a higher prevalence in boys than in girls before puberty and a higher prevalence and severity in women than in men in adulthood. A similar trend is seen in cystic fibrosis with girls having an earlier onset of lung disease at puberty with more frequent pulmonary exacerbations and shorter life span than men in adulthood. Because of the complexity of these diseases, no single straightforward mechanism can explain the gender differences found in asthma and cystic fibrosis. In the latter half of the webinar we will focus on the influence of female sex hormones on CF pulmonary outcomes and summarise data from in vitro and in vivo experiments on how estrogen might modify airway clearance, immunity and bacterial infection in the CF airways. The potential for novel steroid hormone-related therapeutic interventions will also be discussed.

Download a copy of the slides: https://www.xenotech.com/wp-content/uploads/2021/11/Ion-Channel-Targets-of-Dexamethasone-and-Sex-Steroid-Hormones-in-Airway-Disease.pdf
https://www.xenotech.com/about/events/webinar-role-of-udp-glucuronosyltransferases-in-drug-metabolism-and-drug-drug-interactions/
Questions, comments and requests: https://www.xenotech.com/contact/
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/access-adme-research-resources/resource-type/webinar/
Upcoming webinar notifications: https://www.xenotech.com/contact/newsletter-sign-up/
Request a webinar topic: https://www.xenotech.com/contact/webinar-seminar-request/

About the Presenter:
Dr. Brian Harvey is Emeritus Professor of Molecular Medicine at the Royal College of Surgeons in Ireland. He is also a Principal Investigator in the Ion Channel Group at the Centro di Estudios Cientificos, Chile, and Visiting Research Professor at the Sorbonne University, Paris. Brian holds a PhD in Physiology and Biophysics from the National University of Ireland and a DSc honoris causa from Michigan State University. His main research area is in cell and molecular endocrinology of rapid responses to steroid hormones and their regulation of ion channels on which he has published over 300 papers. He is a Chevalier of the French Order of Merit and Member of the Ordre des Palmes Academiques, and an elected fellow of the European Academy of Sciences and the Royal Irish Academy.

Personalized Medicine

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.